Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could presage further deals in STAT6, where ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

While LEO Pharma maintains worldwide rights to topical formulations in dermatology and may co-commercialize oral medicines ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...